HIV – Page 2 – Medxy AI

Efficacy of Bictegravir-Based Regimen vs. Ritonavir-Boosted Protease Inhibitors in HIV Patients on Second-Line Therapy in Haiti: Insights from a Randomized Non-Inferiority Trial

By MedXY 09/21/2025

A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patients.

HIV/AIDS news Nursing & care Pediatrics Specialties

Bridging Pediatric and Adult HIV Care: Evaluating Outcomes and Perspectives from a Novel Transition Clinic for Young People Living with HIV

By MedXY 08/16/2025

This mixed-methods study assesses a novel Adolescent and Young Adult Healthcare Transition (AYA HCT) clinic that achieved high retention but suboptimal viral suppression among youth with HIV, highlighting key strengths and barriers.

Clinical Updates HIV/AIDS Infectious Diseases news Specialties

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

By MedXY 08/05/2025

A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.

Clinical Updates Infectious Diseases Public Health Specialties

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

By MedXY 08/03/2025

MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.

Clinical Updates HIV/AIDS news Specialties

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates HIV/AIDS news Specialties

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

Clinical Updates HIV/AIDS news Specialties

Novel HIV Peptides Identified During Treatment Interruption May Inform Next-Generation Therapeutic Strategies

By MedXY 07/30/2025

Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.

HIV/AIDS news Specialties

Assessing Antibiotic Use During Pregnancy: Impact on Birth Outcomes in HIV Contexts

By MedXY 07/29/2025

A clinical study reveals that trimethoprim-sulfamethoxazole does not significantly improve infant birth weight or related outcomes in HIV-positive pregnancies.